Cure My Disease

Don't miss your cure!

 Log in / Sign up

The Little-Known virus that may rival RSV and flu in older adults

NCT ID NCT07813481

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are tracking 1,000 hospitalized patients aged 65 and older who test positive for a respiratory virus, including human metapneumovirus (hMPV), influenza, RSV, and others. The study compares how each virus relates to death, organ complications, loss of independence, and quality of life over 180 days. The goal is to understand whether hMPV poses a similar threat to older adults as better-known viruses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If hMPV turns out to be as dangerous as RSV or flu for older patients, hospitals could prioritize testing and care for it, and researchers could push harder to develop a vaccine or treatment.
What could go wrong
This is an observational study, so it can show patterns but cannot prove that one virus causes worse outcomes than another. Differences in patients' health, timing, and hospital care could explain the results instead.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged \>65 years with a diagnosis of acute respiratory infection and hospitalized in acute/geriatric wards

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 65 years or older * Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4. * Hospitalized in an Acute Medicine/Geriatrics Unit * Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person. * Affiliated to a social security scheme Exclusion Criteria: * Refusal to participate * Patient deprived of liberty by a judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenovirus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease Coronavinae infectious disease COVID-19 influenza parainfluenza infectious disease respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenovirus Coronavirus Human metapneumovirus (HMPV) Influenza viruses Parainfluenza virus (PIV) Respiratory syncytial virus (RSV) Rhinovirus Severe acute respiratory syndrome coronavirus 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.